Wells Fargo Maintains Overweight on Inari Medical, Lowers Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Inari Medical (NASDAQ:NARI) but lowers the price target from $84 to $65.
July 31, 2024 | 4:08 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on Inari Medical but lowers the price target from $84 to $65.
The lowered price target from $84 to $65 suggests a less optimistic outlook for Inari Medical's stock performance, which could lead to a short-term decline in its stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100